The 2016 AASLD guidelines recommend 180 μg peg-IFN-α, one injection QW for 48 weeks, for treating adult HDV-CH patients [106], since administering increasing doses up to 360 μg QW for up to 5 years or extending peg-IFN-α-2b therapy to 72–102 weeks does not increase the SVR rate over 35% [97,99]. This evidence concerns the gene IFNA2 and cyclic hematopoiesis.